Health
Newer Type 2 diabetes medications could reduce kidney, heart disease risks – News-Medical.Net
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Reviewed by Emily Henderson, B.Sc.Sep 28 2020
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Based on analyses of the clinical trials through March 2020, a group of leading experts in diabetes, heart failure, kidney disease and cardiometabolic disease believe the medicines should be considered for people with CKD and…
-
Noosa News24 hours agoHomicide investigation launched into stabbing death of 39-year-old Brisbane man at Bowen Hills apartment
-
Noosa News23 hours agoMeasles alert issued across popular south-east attractions
-
General23 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
General15 hours agoFrench far-right supporters rally against Le Pen conviction in Paris